Clinical trials: Nutritional Deficiencies
Amyotrophic Lateral Sclerosis (ALS)
Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
The primary objective of the study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip infusion once a day in the patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores…
- Trial name
- NCT01492686
- Testing
- MCI-186, MCI-186 in open label phase
- Where
- Japan
- Volunteers
- 137 people
- Sponsor
- Shionogi
Amyotrophic Lateral Sclerosis
ALS Treatment Extension Study
Treatment extension study for ALS/MND patients who participated in phase 1 study CMD-2016-001, completed assessments following six 28-day cycles of treatment, and whom the Investigator considers would benefit from continued…
- Trial name
- NCT03136809
- Testing
- Cu(II)ATSM
- Where
- Australia
- Volunteers
- 28 people
- Sponsor
- Collaborative Medicinal Development Pty Limited
Poor Nutrition
Benefits of Standard ONS in Indian Adults
This is a prospective, single arm, baseline-controlled multicenter study to observe benefits on Oral Nutritional Supplement (ONS) intake in adults with medical conditions associated with poor nutritional status.
- Trial name
- NCT03713463
- Testing
- Oral Nutritional Supplement (ONS)
- Where
- 45 sites in India
- Volunteers
- 59 people
- Sponsor
- Abbott Nutrition
Malnourished Elderly
Micronutrient and Malnourished Elderly
The purpose of this study is to evaluate the micronutrient status of malnourished elderly after oral nutritional supplementation.
- Trial name
- Reboot (NCT02396121)
- Testing
- Oral nutritional supplement : Renutryl® Booster
- Volunteers
- 67 people
- Sponsor
- Société des Produits Nestlé (SPN)
Hypophosphatasia
Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)
This clinical trial was conducted to study hypophosphatasia (HPP), a bone disorder caused by gene mutations or changes. These gene mutations cause low levels of an enzyme needed to harden bone.
- Trial name
- NCT01163149
- Testing
- asfotase alfa
- Where
- 3 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Malnutrition
Tolerance and Acceptability Evaluation of MONACO
To evaluate tolerance and acceptability of 'MONACO' in patients requiring supplementary oral nutritional support compared with currently available alternatives.
- Trial name
- NCT03836274
- Testing
- AYMES MONACO
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Aymes International Limited
Amyotrophic Lateral Sclerosis (ALS)
A Phase II Study of ALT001 in Patients With Amyotrophic Lateral Sclerosis (ALS)
ALT001 is an allogeneic unrelated human umbilical cord mesenchymal stem cell-derived protein complex under investigation for the treatment of amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT07833618
- Testing
- ALT001 1.0 μg/kg, ALT001 2.0 μg/kg
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Darwin Origin (Hubei) Biopharmaceutical Co., Ltd.
Amyotrophic Lateral Sclerosis
Registry Study of Assistive Devices, Medicines and Healthcare Measures in ALS, SMA and Other Neurological Diseases.
This registry study aims to collect data on the provision of assistive devices, medicines, and other healthcare measures, such as ventilation therapy and nutrition support, in patients with Amyotrophic lateral sclerosis (ALS)…
- Trial name
- NCT05852418
- Where
- 16 sites in Germany
- Volunteers
- 25,000 people
- Sponsor
- Ambulanzpartner Soziotechnologie APST GmbH
Amyotrophic Lateral Sclerosis
RAPA-501 Therapy of ALS Expanded Access Protocol
RAPA-501-ALS is an Intermediate-Size Expanded Access Trial of RAPA-501 autologous hybrid TREG/Th2 T stem cells in patients living with amyotrophic lateral sclerosis (pwALS).
- Trial name
- NCT06169176
- Testing
- RAPA-501 Autologous T stem cells
- Where
- 10 sites in United States
- Sponsor
- Rapa Therapeutics LLC
Iron Deficiency, Anemia
A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease
The purpose of the study is to evaluate the safety and efficacy of intravenous (IV) ferumoxytol compared to IV iron sucrose for the treatment of iron deficiency anemia (IDA) in participants with chronic kidney disease (CKD).
- Conditions
- Iron Deficiency, Anemia, Kidney Disease
- Trial name
- FIRST (NCT01052779)
- Testing
- Ferumoxytol, Iron Sucrose
- Where
- 36 sites in United States, Belgium and 5 more
- Volunteers
- 162 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Malnutrition
Tolerance and Acceptability Evaluation of STOCKHOLM
Tolerance and Acceptability of new oral nutritional supplement - STOCKHOLM.
- Trial name
- NCT03844373
- Testing
- STOCKHOLM
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Aymes International Limited
Amyotrophic Lateral Sclerosis
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
The purpose of this 2-part study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- DAZALS (NCT05407324)
- Testing
- Dazucorilant 300 mg, Dazucorilant 150 mg, Dazucorilant
- Where
- 35 sites in United States, Belgium and 8 more
- Volunteers
- 279 people
- Sponsor
- Corcept Therapeutics
TTR-mediated Amyloidosis, Amyloidosis, Hereditary
Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
The purpose of this study is to provide expanded access of patisiran to patients with hereditary transthyretin-mediated amyloidosis (hATTR).
- Conditions
- TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies
- Trial name
- NCT02939820
- Testing
- patisiran (ALN-TTR02)
- Sponsor
- Alnylam Pharmaceuticals
Malnutrition, Oncology
Effect of Omega 3 Enriched Oral Nutritional Supplement on Nutritional Status of CRC and NSCLC Patients
A single arm intervention study examining the effect of an omega 3 enriched oral nutritional supplement on nutritional status of CRC and NSCLC patients
- Trial name
- OMENS (NCT05495360)
- Testing
- Oral Nutritional Supplement
- Where
- 5 sites in Belgium, Czechia and 1 more
- Volunteers
- 48 people
- Sponsor
- Nutricia Research
Secondary Hyperparathyroidism
Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder
The purpose of this study is to evaluate the effect of thrice weekly intravenous (IV) administration of etelcalcetide in the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney…
- Trial name
- NCT01414114
- Testing
- Etelcalcetide
- Volunteers
- 37 people
- Sponsor
- KAI Pharmaceuticals
Amyotrophic Lateral Sclerosis
Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)
This is a single center, randomized, double-blind, placebo-controlled, 6-month study designed to evaluate the safety, tolerability and clinical responsiveness of MN-166/ibudilast (60 mg/day) when administered as an adjunct to…
- Trial name
- IBU-ALS-1201 (NCT02238626)
- Testing
- MN-166, riluzole
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- MediciNova
Amyloidosis
SAP Depleter Dose Escalation Study in Healthy Volunteers
The purpose of this study is to provide safety information and to define the optimal induction and short term maintenance regimen for GSK2315698 to deplete circulating SAP in healthy volunteers prior to assessing in patients
- Trial name
- NCT01323985
- Testing
- GSK2315698
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Amyotrophic Lateral Sclerosis, ALS
An Efficacy and Safety Study of Ravulizumab in ALS Participants
The purpose of the study is to assess the efficacy and safety of ravulizumab for the treatment of adult participants with ALS.
- Trial name
- NCT04248465
- Testing
- Ravulizumab
- Where
- 95 sites in United States, Australia and 15 more
- Volunteers
- 382 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Iron-deficiency
Study of the Prevalence of Iron Deficiency in Elderly Patient in Hospital Environment
Iron deficiency is defined by insufficient tissue iron stores and anemia is the ultimate stage of iron deficiency. Anemia should never be neglected in an elderly subject because it is associated with an increase in mortality, but…
- Trial name
- CARENFERPA (NCT05514951)
- Testing
- Blood sampling
- Where
- 16 sites in France
- Volunteers
- 888 people
- Sponsor
- Vifor Pharma
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
IC14 for Treatment of Amyotrophic Lateral Sclerosis
Fifty patients with amyotrophic lateral sclerosis that is progressing rapidly will be randomized to receive either the monoclonal antibody IC14 or placebo to be given intravenously over two hours twice weekly for 12 weeks.
- Trial name
- NCT03508453
- Testing
- IC14
- Where
- Australia
- Sponsor
- Implicit Bioscience